Ana Spencer

Ms. Ana Spencer

i3S-Instituto de Investigação e Inovação em Saúde, University of Porto
+2
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ASAna Spencer
Ana Spencer
MTMarília Torrado
Marília Torrado
BCBeatriz Custódio
Beatriz Custódio
SSSara C. Silva-Reis
Sara C. Silva-Reis
SSSofia Duque Santos
Sofia Duque Santos
APAna Paula Pêgo
Ana Paula Pêgo
Central nervous system (CNS) disorders encompass a vast spectrum of pathological conditions and represent a growing concern worldwide. Despite the high social and clinical interest in trying to solve these pathologies, there are many challenges to bridge in order to achieve an effective therapy. One of the main obstacles to advancements in this field that has hampered many of the therapeutic strategies proposed to date is the presence of the CNS barriers that restrict the access to the brain. However, adequate brain biodistribution and neuronal cells specific accumulation in the targeted site also represent major hurdles to the attainment of a successful CNS treatment. Over the last few years, nanotechnology has taken a step forward towards the development of therapeutics in neurologic diseases and different approaches have been developed to surpass these obstacles. The versatility of the designed nanocarriers in terms of physical and chemical properties, and the possibility to functionalize them with specific moieties, have resulted in improved neurotargeted delivery profiles. With the concomitant progress in biology research, many of these strategies have been inspired by nature and have taken advantage of physiological processes to achieve brain delivery. Here, the different nanosystems and targeting moieties used to achieve a neuronal delivery reported in the open literature are comprehensively reviewed and critically discussed, with emphasis on the most recent bioinspired advances in the field. Finally, we express our view on the paramount challenges in targeted neuronal delivery that need to be overcome for these promising therapeutics to move from the bench to the bedside.

1 September 2018 in Acta Biomaterialia
Verified
Journal Article
Closed access
CGCarla Pereira Gomes
Carla Pereira Gomes
VLVictoria Leiro
Victoria Leiro
CLCátia Daniela Ferreira Lopes
Cátia Daniela Ferreira Lopes
ASAna Spencer
Ana Spencer
APAna Paula Pêgo
Ana Paula Pêgo

31 May 2017 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
VLVictoria Leiro
Victoria Leiro
JGJoão Pedro Garcia
João Pedro Garcia
PMPedro M. D. Moreno
Pedro M. D. Moreno
ASAna Spencer
Ana Spencer
MFMarcos Fernandez-Villamarin
Marcos Fernandez-Villamarin
APAna Paula Pêgo
Ana Paula Pêgo
New hybrid-biodegradable PEG–dendritic block copolymers as versatile delivery vectors for biomedical applications. Here, their biofunctionality as siRNA vectors is presented.

14 December 2022 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
ASAna Spencer
Ana Spencer
VLVictoria Leiro
Victoria Leiro
APAna Paula Pêgo
Ana Paula Pêgo
Nanomedicines based on nanoparticles as carriers of therapeutics are expected to drastically influence the future of healthcare. However, clinical translation of these technologies can be very challenging. The development process of nanoparticles for biological applications encompasses the analysis and understanding of several steps in vitro, before in vivo, and subsequent clinical applications, namely, the in-depth study of biosafety, cellular interaction, and intracellular trafficking. Recently, we proposed a new family of fully biodegradable PEG-GATGE (Poly(Ethylene Glycol)-Gallic Acid-Triethylene Glycol Ester) dendritic block copolymers to act as versatile delivery vectors in nanomedicine. These nanosystems showed great promise in complexing, protecting, and delivering nucleic acids to cells, forming nanoscaled complexes called dendriplexes. Due to these favourable features, in the present study, the dendriplexes’ characterization was expanded and, in addition, their biocompatibility, cellular uptake, and cellular path in neuronal cells from the peripheral and central nervous systems were assessed. Our fully biodegradable dendritic nanosystem was found to be biocompatible in all the studied neuronal cells and mediates fast cellular interaction and endocytosis in both cell line tested and primary mouse cortical neurons. Nevertheless, the mechanism of dendriplex cell entry and intracellular fate was found to be different in cell lines and primary cultures. Dendriplexes’ internalization was observed to be mediated by clathrin in ND7/23 and HT22 cells, while caveolin-mediated endocytosis occurred in primary mouse cortical neurons, in which, after internalization, dendriplexes were not colocalized with lysosomes or autophagosomes. Taken together, these results further point to PEG-GATGE dendrimers as biosafe delivery vectors of nucleic acids to neuronal cells in vitro, suggesting their feasibility as carriers in the context of nervous system applications. Furthermore, our data reinforce the importance of testing the performance of new vectors in different models to verify their potential applicability in vitro and/or in vivo.

13 May 2025 in Advanced Healthcare Materials
Verified
Journal Article
Open access
ASAna Spencer
Ana Spencer
AVAdriana Vilaça
Adriana Vilaça
Miguel XavierMiguel Xavier
Miguel Xavier
RSRafael Santos
Rafael Santos
AIAriel Ionescu
Ariel Ionescu
APAna Paula Pêgo
Ana Paula Pêgo
Gene therapy using small interfering RNA (siRNA) holds promise for treating neurological disorders by silencing specific genes, like the phosphatase and tensin homolog (PTEN) gene, which restricts axonal growth. Effective siRNA delivery to neurons, however, poses challenges due to premature nucleic acid degradation and unspecific delivery. Chitosan‐based delivery systems, noted for their biocompatibility, face limitations such as low transfection efficiency and lack of neurotropism. Building on the previous successes with neuron‐targeted DNA delivery using chitosan, a novel approach for siRNA delivery aimed at PTEN downregulation is proposed. This involves using thiolated trimethyl chitosan (TMCSH)–based siRNA nanoparticles functionalized with the neurotropic C‐terminal fragment of the tetanus neurotoxin heavy chain (HC) for efficient delivery to peripheral and central neurons. These polyplexes demonstrate suitable physicochemical properties, biocompatibility, and no adverse effects on neuronal electrophysiology. Diverse neuronal models, including 3D ex vivo cultures and microfluidics, confirm the polyplexes’ efficiency and neurospecificity. HC‐functionalization significantly enhances neuronal binding, and live cell imaging reveals fivefold faster retrograde transport along axons. Furthermore, siRNA delivery targeting PTEN promoted axonal outgrowth in embryonic cortical neurons. In conclusion, the proposed polyplexes represent a promising platform for neuronal siRNA delivery, offering potential for clinical translation and therapeutic applications.

3 October 2021 in Nanomaterials
Verified
Journal Article
Open access
PDF file
HSHuw Summers
Huw Summers
CGCarla P. Gomes
Carla P. Gomes
AVAida Varela-Moreira
Aida Varela-Moreira
ASAna Spencer
Ana Spencer
MLMaria Gomez Lazaro
Maria Gomez Lazaro
PRPaul Rees
Paul Rees
Nanoparticle drug delivery vehicles introduce multiple pharmacokinetic processes, with the delivery, accumulation, and stability of the therapeutic molecule influenced by nanoscale processes. Therefore, considering the complexity of the multiple interactions, the use of data-driven models has critical importance in understanding the interplay between controlling processes. We demonstrate data simulation techniques to reproduce the time-dependent dose of trimethyl chitosan nanoparticles in an ND7/23 neuronal cell line, used as an in vitro model of native peripheral sensory neurons. Derived analytical expressions of the mean dose per cell accurately capture the pharmacokinetics by including a declining delivery rate and an intracellular particle degradation process. Comparison with experiment indicates a supply time constant, τ = 2 h. and a degradation rate constant, b = 0.71 h−1. Modeling the dose heterogeneity uses simulated data distributions, with time dependence incorporated by transforming data-bin values. The simulations mimic the dynamic nature of cell-to-cell dose variation and explain the observed trend of increasing numbers of high-dose cells at early time points, followed by a shift in distribution peak to lower dose between 4 to 8 h and a static dose profile beyond 8 h.